What is Universe Pharmaceuticals Inc's earnings per share (EPS)?

Universe Pharmaceuticals Inc (UPC) reported diluted earnings per share of $-8.06 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Universe Pharmaceuticals Inc Financials

UPC

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2025 Currency USD FYE September

This page shows Universe Pharmaceuticals Inc (UPC) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI UPC FY2025 2026-04-22

At Universe Pharmaceuticals, a cash-rich balance sheet is masking a smaller operating base still reliant on financing inflows.

From FY2023 to FY2025, revenue fell from $32.3M to $17.9M, yet the operating loss narrowed rather than widened. Gross margin rebounded from 31.9% to 35.3%, suggesting the company resized costs faster than sales declined, but it still did not turn that improvement into positive operating cash flow.

FY2025 cash of $33.6M exceeded total liabilities of $13.2M, leaving a cash-heavy balance sheet despite ongoing losses. A current ratio of 4.1x and financing inflows of $9.7M, after a much larger financing inflow in FY2024, show near-term liquidity is being maintained externally rather than through operations.

Receivables stayed near $13.0M in FY2025 even as revenue fell to $17.9M, so sales are not quickly becoming cash. R&D spending dropped to $672K from $4.9M in FY2023, meaning the narrower loss partly reflects lower reinvestment rather than a full operating recovery.

Financial Health Signals

Financial Health Score 48/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Universe Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Balance Sheet

Altman Z-Score Distress

0.69

Universe Pharmaceuticals Inc scores 0.69, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Universe Pharmaceuticals Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

1.38x

For every $1 of reported earnings, Universe Pharmaceuticals Inc generates $1.38 in operating cash flow (-$5.1M OCF vs -$3.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-10.1x

Universe Pharmaceuticals Inc earns $-10.1 in operating income for every $1 of interest expense (-$2.9M vs $289K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$17.9M

YoY-22.4%

5Y CAGR-10.3%

Universe Pharmaceuticals Inc generated $17.9M in revenue in fiscal year 2025. This represents a decrease of 22.4% from the prior year.

EBITDA

-$2.4M

YoY+68.2%

Universe Pharmaceuticals Inc's EBITDA was -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 68.2% from the prior year.

Net Income

-$3.7M

YoY+57.9%

Universe Pharmaceuticals Inc reported -$3.7M in net income in fiscal year 2025. This represents an increase of 57.9% from the prior year.

EPS (Diluted)

$-8.06

Universe Pharmaceuticals Inc earned $-8.06 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$5.3M

YoY+45.2%

Universe Pharmaceuticals Inc generated -$5.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.2% from the prior year.

Cash & Debt

$33.6M

YoY+13.9%

5Y CAGR+27.3%

Universe Pharmaceuticals Inc held $33.6M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

563,338

Universe Pharmaceuticals Inc had 563,338 shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

35.3%

YoY+8.9pp

5Y CAGR-10.6pp

Universe Pharmaceuticals Inc's gross margin was 35.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 8.9 percentage points from the prior year.

Operating Margin

-16.3%

YoY+18.5pp

5Y CAGR-49.7pp

Universe Pharmaceuticals Inc's operating margin was -16.3% in fiscal year 2025, reflecting core business profitability. This is up 18.5 percentage points from the prior year.

Net Margin

-20.6%

YoY+17.3pp

5Y CAGR-45.2pp

Universe Pharmaceuticals Inc's net profit margin was -20.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 17.3 percentage points from the prior year.

Return on Equity

-6.5%

YoY+12.6pp

5Y CAGR-42.9pp

Universe Pharmaceuticals Inc's ROE was -6.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 12.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$672K

YoY-77.8%

5Y CAGR+2.9%

Universe Pharmaceuticals Inc invested $672K in research and development in fiscal year 2025. This represents a decrease of 77.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$267K

YoY+28.1%

5Y CAGR+38.8%

Universe Pharmaceuticals Inc invested $267K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 28.1% from the prior year.

UPC Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$17.9M-22.4%	$23.0M-28.7%	$32.3M-19.5%	$40.1M-16.3%	$48.0M+56.3%	$30.7M
Cost of Revenue	$11.6M-31.8%	$17.0M-22.9%	$22.0M+36.1%	$16.2M-12.3%	$18.4M+49.4%	$12.3M
Gross Profit	$6.3M+3.8%	$6.1M-41.1%	$10.3M-52.9%	$21.9M-13.6%	$25.3M+79.7%	$14.1M
R&D Expenses	$672K-77.8%	$3.0M-37.6%	$4.9M-36.4%	$7.6M+39.9%	$5.5M+837.3%	$583K
SG&A Expenses	$3.7M+29.7%	$2.9M+9.5%	$2.6M+20.9%	$2.2M-33.8%	$3.3M+93.5%	$1.7M
Operating Income	-$2.9M+63.6%	-$8.0M-102.2%	-$4.0M+43.5%	-$7.0M-151.7%	$13.6M+32.6%	$10.3M
Interest Expense	$289K-5.0%	$305K+60.1%	$190K+17.1%	$162K+59.8%	$102K-17.9%	$124K
Income Tax	N/A	$607K-73.1%	$2.3M+176.4%	$815K-65.4%	$2.4M-7.2%	$2.5M
Net Income	-$3.7M+57.9%	-$8.7M-32.6%	-$6.6M+16.8%	-$7.9M-169.9%	$11.3M+49.8%	$7.6M
EPS (Diluted)	$-8.06	$-626.96	$-1089.21	$-1309.11-36667.3%	$3.58+661.7%	$0.47

Metric	Q4'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UPC Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$69.3M+2.0%	$68.0M+62.9%	$41.7M-29.9%	$59.5M-15.1%	$70.1M+143.5%	$28.8M
Current Assets	$53.6M+3.8%	$51.6M+104.3%	$25.3M-39.1%	$41.5M-17.8%	$50.5M+116.8%	$23.3M
Cash & Equivalents	$33.6M+13.9%	$29.5M+458.1%	$5.3M-7.5%	$5.7M-29.3%	$8.1M-19.7%	$10.1M
Inventory	$2.2M+26.3%	$1.7M-48.0%	$3.3M+51.5%	$2.2M-10.4%	$2.5M+29.2%	$1.9M
Accounts Receivable	$13.0M+0.8%	$12.9M+17.2%	$11.0M-27.5%	$15.2M-2.5%	$15.6M+43.2%	$10.9M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.2M-41.3%	$22.5M+63.2%	$13.8M-43.2%	$24.2M+4.6%	$23.2M+189.4%	$8.0M
Current Liabilities	$13.2M-35.1%	$20.3M+47.7%	$13.8M+5.0%	$13.1M+16.8%	$11.2M+40.1%	$8.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$56.1M+23.4%	$45.5M+62.7%	$28.0M-20.8%	$35.3M-24.8%	$47.0M+125.9%	$20.8M
Retained Earnings	-$13.8M-36.1%	-$10.2M-604.3%	-$1.4M-108.8%	$16.3M-34.9%	$25.1M+82.4%	$13.7M

Metric	Q4'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Total Assets	$69.3M+2.0%	$68.0M+37.5%	$49.4M+18.5%	$41.7M-40.7%	$70.4M+18.2%	$59.5M-16.6%	$71.4M+1.7%	$70.1M
Current Assets	$53.6M+3.8%	$51.6M+54.0%	$33.5M+32.7%	$25.3M-51.9%	$52.5M+26.5%	$41.5M-19.7%	$51.7M+2.3%	$50.5M
Cash & Equivalents	$33.6M+13.9%	$29.5M+232.9%	$8.9M+67.7%	$5.3M-59.2%	$13.0M+126.8%	$5.7M-59.9%	$14.2M+76.2%	$8.1M
Inventory	$2.2M+26.3%	$1.7M-48.7%	$3.4M+1.3%	$3.3M+16.6%	$2.9M+30.0%	$2.2M-34.8%	$3.4M+37.5%	$2.5M
Accounts Receivable	$13.0M+0.8%	$12.9M-10.3%	$14.4M+30.6%	$11.0M-37.1%	$17.5M+15.4%	$15.2M-19.3%	$18.8M+20.8%	$15.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.2M-41.3%	$22.5M-1.0%	$22.7M+64.9%	$13.8M-40.8%	$23.2M-4.0%	$24.2M+137.2%	$10.2M-55.9%	$23.2M
Current Liabilities	$13.2M-35.1%	$20.3M-1.4%	$20.6M+49.8%	$13.8M-40.8%	$23.2M+77.5%	$13.1M+28.3%	$10.2M-8.9%	$11.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$56.1M+23.4%	$45.5M+70.1%	$26.7M-4.4%	$28.0M-40.6%	$47.1M+33.4%	$35.3M-42.2%	$61.2M+30.1%	$47.0M
Retained Earnings	-$13.8M-36.1%	-$10.2M-245.7%	-$2.9M-103.7%	-$1.4M-109.3%	$15.6M-4.4%	$16.3M-39.1%	$26.8M+6.9%	$25.1M

UPC Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.1M+46.9%	-$9.5M-951.3%	$1.1M+185.8%	-$1.3M+36.7%	-$2.1M-133.6%	$6.1M
Capital Expenditures	$267K+28.1%	$208K+371.6%	$44K-52.9%	$94K-78.9%	$445K+758.2%	$52K
Free Cash Flow	-$5.3M+45.2%	-$9.7M-1005.7%	$1.1M+176.9%	-$1.4M+44.2%	-$2.5M-141.2%	$6.1M
Investing Cash Flow	-$342K+5.4%	-$361K-718.0%	-$44K+98.9%	-$3.9M+85.6%	-$27.1M-52141.3%	-$52K
Financing Cash Flow	$9.7M-71.4%	$34.0M+2541.6%	-$1.4M-141.9%	$3.3M-87.5%	$26.6M+5554.1%	$470K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

UPC Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	35.3%+8.9pp	26.4%-5.6pp	31.9%-22.6pp	54.5%+1.7pp	52.8%+6.9pp	45.9%
Operating Margin	-16.3%+18.5pp	-34.8%-22.5pp	-12.3%+5.2pp	-17.5%-45.8pp	28.3%-5.1pp	33.4%
Net Margin	-20.6%+17.3pp	-37.9%-17.5pp	-20.4%-0.7pp	-19.7%-43.3pp	23.6%-1.0pp	24.6%
Return on Equity	-6.5%+12.6pp	-19.2%+4.4pp	-23.5%-1.1pp	-22.4%-46.5pp	24.1%-12.2pp	36.3%
Return on Assets	-5.3%+7.5pp	-12.8%+2.9pp	-15.8%-2.5pp	-13.3%-29.4pp	16.1%-10.1pp	26.2%
Current Ratio	4.07+1.5	2.54+0.7	1.84-1.3	3.17-1.3	4.50+1.6	2.91
Debt-to-Equity	0.23-0.3	0.490.0	0.49-0.2	0.69+0.2	0.49+0.1	0.38
FCF Margin	-29.8%+12.4pp	-42.2%-45.5pp	3.3%+6.8pp	-3.5%+1.7pp	-5.2%-25.0pp	19.8%

Metric	Q4'25	Q4'24	Q2'24	Q4'23	Q2'23	Q4'22	Q2'22	Q4'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	4.07+1.5	2.54+0.9	1.63-0.2	1.84-0.4	2.26-0.9	3.17-1.9	5.06+0.6	4.50
Debt-to-Equity	0.23-0.3	0.49-0.4	0.85+0.4	0.490.0	0.49-0.2	0.69+0.5	0.17-0.3	0.49
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

AKANDA CORP AKAN

$5.4M

PRF Technologies Ltd. PRFX

$4.3M

SHUTTLE PHARMACTCLS HLDGS INC SHPH

$1.9M

Redhill Biopharm RDHL

$4.3M

Cbdmd Inc YCBD

$8.5M

Frequently Asked Questions

What is Universe Pharmaceuticals Inc's annual revenue?

Universe Pharmaceuticals Inc (UPC) reported $17.9M in total revenue for fiscal year 2025. This represents a -22.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Universe Pharmaceuticals Inc's revenue growing?

Universe Pharmaceuticals Inc (UPC) revenue declined by 22.4% year-over-year, from $23.0M to $17.9M in fiscal year 2025.

Is Universe Pharmaceuticals Inc profitable?

No, Universe Pharmaceuticals Inc (UPC) reported a net income of -$3.7M in fiscal year 2025, with a net profit margin of -20.6%.

What is Universe Pharmaceuticals Inc's EBITDA?

Universe Pharmaceuticals Inc (UPC) had EBITDA of -$2.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Universe Pharmaceuticals Inc's gross margin?

Universe Pharmaceuticals Inc (UPC) had a gross margin of 35.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Universe Pharmaceuticals Inc's operating margin?

Universe Pharmaceuticals Inc (UPC) had an operating margin of -16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Universe Pharmaceuticals Inc's net profit margin?

Universe Pharmaceuticals Inc (UPC) had a net profit margin of -20.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Universe Pharmaceuticals Inc's return on equity (ROE)?

Universe Pharmaceuticals Inc (UPC) has a return on equity of -6.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Universe Pharmaceuticals Inc's free cash flow?

Universe Pharmaceuticals Inc (UPC) generated -$5.3M in free cash flow during fiscal year 2025. This represents a 45.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Universe Pharmaceuticals Inc's operating cash flow?

Universe Pharmaceuticals Inc (UPC) generated -$5.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Universe Pharmaceuticals Inc's total assets?

Universe Pharmaceuticals Inc (UPC) had $69.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Universe Pharmaceuticals Inc's capital expenditures?

Universe Pharmaceuticals Inc (UPC) invested $267K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Universe Pharmaceuticals Inc spend on research and development?

Universe Pharmaceuticals Inc (UPC) invested $672K in research and development during fiscal year 2025.

How many shares does Universe Pharmaceuticals Inc have outstanding?

Universe Pharmaceuticals Inc (UPC) had 563,338 shares outstanding as of fiscal year 2025.

What is Universe Pharmaceuticals Inc's current ratio?

Universe Pharmaceuticals Inc (UPC) had a current ratio of 4.07 as of fiscal year 2025, which is generally considered healthy.

What is Universe Pharmaceuticals Inc's debt-to-equity ratio?

Universe Pharmaceuticals Inc (UPC) had a debt-to-equity ratio of 0.23 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Universe Pharmaceuticals Inc's return on assets (ROA)?

Universe Pharmaceuticals Inc (UPC) had a return on assets of -5.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Universe Pharmaceuticals Inc's cash runway?

Based on fiscal year 2025 data, Universe Pharmaceuticals Inc (UPC) had $33.6M in cash against an annual operating cash burn of $5.1M. This gives an estimated cash runway of approximately 80 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Universe Pharmaceuticals Inc's Altman Z-Score?

Universe Pharmaceuticals Inc (UPC) has an Altman Z-Score of 0.69, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Universe Pharmaceuticals Inc's Piotroski F-Score?

Universe Pharmaceuticals Inc (UPC) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Universe Pharmaceuticals Inc's earnings high quality?

Universe Pharmaceuticals Inc (UPC) has an earnings quality ratio of 1.38x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Universe Pharmaceuticals Inc cover its interest payments?

Universe Pharmaceuticals Inc (UPC) has an interest coverage ratio of -10.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Universe Pharmaceuticals Inc?

Universe Pharmaceuticals Inc (UPC) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.